Here is how Quest Diagnostics (DGX) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Quest Diagnostics $DGX (DGX) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Quest Diagnostics is one of 884 companies in the Medical group. The Medical group currently sits at #7 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Quest Diagnostics is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for DGX's full-year earnings has moved 1.2% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, DGX has returned 12.5% so far this year. Meanwhile, the Medical sector has returned an average of -5.4% on a year-to-date basis. This means that Quest Diagnostics is outperforming the sector as a whole this year.
One other Medical stock that has outperformed the sector so far this year is DaVita HealthCare (DVA). The stock is up 74.7% year-to-date.
For DaVita HealthCare, the consensus EPS estimate for the current year has increased 6.4% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
Breaking things down more, Quest Diagnostics is a member of the Medical - Outpatient and Home Healthcare industry, which includes 14 individual companies and currently sits at #50 in the Zacks Industry Rank. Stocks in this group have gained about 5.2% so far this year, so DGX is performing better this group in terms of year-to-date returns. DaVita HealthCare is also part of the same industry.
Quest Diagnostics and DaVita HealthCare could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X $TWTR Imaging which shot up +129.6% in little more than 9 months.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Join 500,000+ readers who start their day with Quartz.
By subscribing, you agree to our Terms of Service and Privacy Policy.
